A new subgroup analysis of the VOYAGER-PAD trial revealed whether adding clopidogrel to the rivaroxaban and aspirin regime of a patient with peripheral artery disease (PAD) at the time of revascularization is beneficial. In this podcast, William R. Hiatt, MD, provides insight into the analysis results.
The topic is one he presented about during a late-breaking clinical trial session, “The Benefit and Risk of Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease After Lower Extremity Revascularization (LER) With and Without Concomitant Clopidogrel: a Key Subgroup Analysis From VOYAGER-PAD,” at ACC.20/WCC Virtual.
Additional Resources:
- Hiatt WR. The benefit and risk of rivaroxaban plus aspirin in patients with peripheral artery disease after lower extremity revascularization (LER) with and without concomitant clopidogrel: a key subgroup analysis from VOYAGER-PAD. Paper presented at: the American College of Cardiology Virtual Annual Scientific Session Together With World Congress of Cardiology; March 28-30, 2020; virtual. https://acc.mediasite.com/mediasite/play/88b2f2ea2d8a4c74ae7e088073b858981d?autoStart=true. Accessed April 22, 2020.
- Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. Published online March 28, 2020. doi:10.1056/NEJMoa2000052
- Mehta SR, Yusuf S, CURE study investigators. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J. 2000;21(24):2033-2041.doi:10.1053/euhj.2000.2474
William R. Hiatt, MD, is a professor of medicine with the Division of Cardiology at the University of Colorado School of Medicine. He is also senior clinician—scientist for Colorado Prevention Center Clinical Research.